Ecer asks for your consent to use your personal data to:
Personalised advertising and content, advertising and content measurement, audience research and services development
Store and/or access information on a device
Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with 135 TCF vendor(s) and 65 ad partner(s), or used specifically by this site or app.
Some vendors may process your personal data on the basis of legitimate interest, which you can object to by do not consent. Contact our platform customer service, you can also withdraw your consent.
Your message must
be between 20-3,000 characters!
Submit Requirement
Thank You!
Your requirement has been sent. we will contact you quickly!
{"title":"Everolimus Cas:159351-69-6","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/13\/50\/eba1c24c4a28ac53d402d0111258-200x200-1\/everolimus_cas_3a159351_69_6.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"159351-69-6"}}
{"title":"Pharmaceutical Triciribine CAS:35943-35-2","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/05\/f2\/5bf7a84ba217658116748411cd5f-200x200-1\/pharmaceutical_triciribine_cas_3a35943_35_2.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"35943-35-2"}}
{"title":"Nocodazole CAS: 31430-18-9","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/ac\/78\/1274d18e6f3ee306f71ae1820b7c-200x200-1\/nocodazole_cas_3a_31430_18_9.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"31430-18-9"}}
{"title":"China Product Apixaban CAS:503612-47-3","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/d7\/6a\/f27c203ac2139c3079e534d35b10-200x200-1\/china_product_apixaban_cas_3a503612_47_3.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"503612-47-3"}}
{"title":"Bexarotene CAS: 153559-49-0","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/19\/32\/4d1d7c25f8e1a345156bf531f721-200x200-1\/bexarotene_cas_3a_153559_49_0.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"153559-49-0"}}
{"title":"DMXAA CAS: 117570-53-3","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/70\/51\/d404b8f03fd334a2f8e2301d3f38-200x200-1\/dmxaa_cas_3a_117570_53_3.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"117570-53-3"}}
{"title":"Fadrozole hydrochloride CAS: 102676-31-3","imgUrl":"https:\/\/img.silkroadsl.com\/nimg\/ed\/c5\/a195643d06fc410b672ce102b1b3-200x200-1\/fadrozole_hydrochloride_cas_3a_102676_31_3.jpg","attrs":{"Place of Origin":"China","Certification":"ISO,SGS","Model Number":"102676-31-3"}}
In vitro Everolimus exhibits the immunosuppressive activity which is comparable to that of rapamycin. Everolimus competes with immobilized FK 506 for binding to biotinylated FKBP12 and shows the inhibitory effect on a two-way MLR performed with spleen cells from BALB/c and CBA mice with IC50 of 0.12-1.8 nM. [1] Everolimus also shows antiangiogenic/vascular effects in VEGF-induced HUVEC proliferation with IC50 of 0.12 nM and bFGF-induced HUVEC proliferation with IC50 of 0.8 nM, respectively. [2] A recent study shows that Everolimus shows a dose-dependent inhibitory effects on both the total cells and the stem cells from the BT474 cell line and the primary breast cancer cells with IC50 of 156 nM in total cells of primary breast cancer cells and 71 nM in total cells of BT474 cells. In addition, combination treatment with Everolimus and trastuzumab produces the significantly increased inhibition on the growth of cancer stem cells with the inhibition rate increased by more than 50 %. [3]
In vivo Everolimus (0.1 to 10 mg/kg) dose-dependently inhibits growth of the primary (ear) and lymph node metastases of B16/BL6 melanoma, with decreased total number of vessels and reduced mature vessels. [2] In a xenograft animal model of BT474 stem cells, Everolimus shows significant reductions in mean tumor sizes (590.6 mm3), compared to the control group with a tumor size of 698 mm3. Furthermore, combination treatment with Everolimus and trastuzumab significantly decreases the xenograft tumor size (410.8 mm3) more than Everolimus treatment alone. [3]
Company Details
Bronze Gleitlager
,
Bronze Sleeve Bushings
and
Graphite Plugged Bushings
from Quality China Factory
Business Type:
Manufacturer,Exporter
Year Established:
2008
Total Annual:
5000000-100000000
Employee Number:
30-50
Ecer Certification:
Active Member
Beijing Topwin Technology Co.,Ltd. is a high-tech
enterprise located in Beijing which was built in
2008,specializing in R&D, manufacturing, sales,
import and export trade of ...
Beijing Topwin Technology Co.,Ltd. is a high-tech
enterprise located in Beijing which was built in
2008,specializing in R&D, manufacturing, sales,
import and export trade of ...